Anti-CD19-Therapien: der kommende Goldstandard für die IgG4-assoziierten Erkrankungen
Crossref DOI link: https://doi.org/10.1007/s00393-025-01682-4
Published Online: 2025-07-31
Published Print: 2025-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Krusche, Martin
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Text and Data Mining valid from 2025-07-31
Version of Record valid from 2025-07-31
Article History
Accepted: 24 June 2025
First Online: 31 July 2025
Interessenkonflikt
: M. Krusche: Vortragshonorar von Amgen.